Ragon Institute of Mass General, MIT, and Harvard
Thang Long "Andrew" Ngo is a skilled research technician currently working at the Ragon Institute of Mass General, MIT, and Harvard since July 2023, specifically in the Allen Lab. Previously, from January 2021 to May 2023, Ngo served as an undergraduate researcher at Boston University School of Medicine, focusing on the effects of differential CD4+ T cell activation signaling on HIV latency, with research presented at the BU Annual Undergraduate Research Symposium in October 2022. Additionally, Ngo was a student health ambassador at Boston University and an assistant instructor for the FY101 course, contributing to the First Year Experience Program. An internship as a drug quality control intern at Tatra Pharmaceutical Co., Ltd. involved validating concentrations of various substances using advanced chromatography techniques. Ngo began research early, screening antibody fragments targeting CD32a at Oregon Episcopal School from March 2017 to May 2019. Ngo holds a Bachelor of Arts with Honors in Biochemistry and Molecular Biology from Boston University and a high school diploma from Oregon Episcopal School.
This person is not in the org chart
Ragon Institute of Mass General, MIT, and Harvard
1 followers
The Ragon Institute was established in 2009 with a dual mission: to contribute to the accelerated discovery of an HIV/AIDS vaccine and subsequently establish itself as a world leader in the collaborative study of immunology. Founded with a commitment of $100 million from Phillip T. (Terry) and Susan M. Ragon, and with an additional $200 million gift to endow the Institute announced on April 26, 2019, the Institute is structured and positioned to significantly contribute to a global effort to successfully develop an HIV/AIDS vaccine by: • Creating non-traditional partnerships among experts with different but complementary backgrounds; • Providing a means for rapidly funding promising studies; • Integrating key facets of vaccine development efforts that have tended to follow separate tracks; • Providing a substantial pool of accessible, flexible funding that lowers the threshold for scientists to pursue risky, unconventional avenues of study that are unlikely to attract funding from traditional sources. Such funding encourages innovation, compresses the time it takes to conduct bench-to-bedside research and attracts new minds to the field. The Ragon Institute creates a singular opportunity and environment to engage scientists, engineers and clinicians in challenging research for which there is no greater benefit – saving lives and curing the ill.